Pre-Made Rozibafusp Alfa Biosimilar, Fusion Protein targeting ICOS fused with human TNFSF13B (tumor necrosis factor (TNF) superfamily member 13B, BAFF, THANK, TALL1, TALL-1, BLYS, BLyS, B cell activating factor, B lymphocyte activator, CD257): Recombinant therapeutic protein targeting AILIM/CD278/CVID1 for drug discovery and mechanism of action (MOA) research

Pre-Made Rozibafusp Alfa Biosimilar, Fusion Protein targeting ICOS fused with human TNFSF13B (tumor necrosis factor (TNF) superfamily member 13B, BAFF, THANK, TALL1, TALL-1, BLYS, BLyS, B cell activating factor, B lymphocyte activator, CD257): Recombinant therapeutic protein targeting AILIM/CD278/CVID1 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Autoimmune diseases, including systemic lupus erythematosus (SLE), are associated with dysregulated T cell and B cell responses. Rozibafusp alfa is a bispecific molecule targeting T cell and B cell activity through inhibition of the inducible costimulator ligand (ICOSL) and the B cell activating factor (BAFF). Targeting both ICOSL and BAFF will be more effective than single target inhibition in SLE and other autoimmune diseases.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-982-1mg	1mg	3090
GMP-Bios-INN-982-10mg	10mg	Inquiry
GMP-Bios-INN-982-100mg	100mg	Inquiry
GMP-Bios-INN-982-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Rozibafusp Alfa Biosimilar, Fusion Protein targeting ICOS fused with human TNFSF13B (tumor necrosis factor (TNF) superfamily member 13B, BAFF, THANK, TALL1, TALL-1, BLYS, BLyS, B cell activating factor, B lymphocyte activator, CD257): Recombinant therapeutic protein targeting AILIM/CD278/CVID1
INN Name	Rozibafusp Alfa
Target	ICOS
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	IgG2 - kappa
VD LC	IgG2 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Amgen (Thousand Oaks CA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0